Until December 2020, the European Commission approved inclisiran (a small interfering RNA targeting hepatic PCSK9 synthesis) with an infrequent dosing for heterozygous familial hypercholesterolemia (starting with an initial dose, then administered again at 3 months and then every 6 months thereafter), based on an LDL-C reduction of −47.9% [27]. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.